Literature DB >> 12011818

Tissue distribution of imipenem in critically ill patients.

Irmgard Tegeder1, Achim Schmidtko, Lutz Bräutigam, Andreas Kirschbaum, Gerd Geisslinger, Jörn Lötsch.   

Abstract

BACKGROUND AND METHODS: Imipenem is a broad-spectrum antibiotic used mainly for serious infections in critically ill patients. Because the infection originates mostly from a certain tissue, we assessed tissue concentrations of imipenem using microdialysis in patients in intensive care with serious infections compared with healthy volunteers. Most patients were >60 years old and had renal failure; most patients also had impaired liver, heart, or lung function.
RESULTS: Muscle and subcutaneous tissue concentrations in patients (maximum of 2.3 +/- 1.5 microg/mL for both muscle and subcutaneous tissue) were significantly lower than those in healthy subjects (maximum of 12.8 +/- 1.6 and 10.7 +/- 1.0 microg/mL for muscle and subcutaneous tissue). The tissue distribution rate constants for muscle and subcutaneous tissue were also significantly lower in patients (1.95 +/- 0.6 and 1.1 +/- 0.2 h(-l), respectively) than in healthy subjects (5.2 +/- 1.0 and 6.6 +/- 1.7 h(-1), respectively), meaning that tissue distribution in patients was reduced and retarded. Values for area under the plasma concentration-time curve did not significantly differ between patients and healthy subjects (37.4 +/- 5.9 microg. h/mL and 46.0 +/- 4.4 microg. h/mL, respectively,) although the elimination of imipenem in patients was prolonged (clearance, 6.3 +/- 0.8 L/h and 13.2 +/- 1.4 L/h in patients and healthy subjects, respectively).
CONCLUSIONS: Our data suggest that the amount and velocity of imipenem tissue distribution in seriously ill patients is reduced compared with those values in healthy volunteers. Dose adjustments that are exclusively based on plasma concentration data may therefore be misleading and may result in potential underdosing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12011818     DOI: 10.1067/mcp.2002.122526

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  38 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Authors:  Markus Müller; Amparo dela Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 2.  Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future.

Authors:  Christian Joukhadar; Markus Müller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Prospective determination of plasma imipenem concentrations in critically ill children.

Authors:  Eric Giannoni; Philippe Moreillon; Jacques Cotting; Adrien Moessinger; Jacques Bille; Laurent Décosterd; Giorgio Zanetti; Paul Majcherczyk; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.

Authors:  Cornelia Buerger; Nele Plock; Pejman Dehghanyar; Christian Joukhadar; Charlotte Kloft
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

5.  Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of Acinetobacter baumannii-infected rats.

Authors:  Claire Dahyot; Sandrine Marchand; Greisiele Lorena Pessini; Claudine Pariat; Bertrand Debaene; William Couet; Olivier Mimoz
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  Microdialysis study of imipenem distribution in the intraperitoneal fluid of rats with or without experimental peritonitis.

Authors:  Sandrine Lefeuvre; Sandrine Marchand; Isabelle Lamarche; Olivier Mimoz; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

7.  Application of basic pharmacokinetic concepts to analysis of microdialysis data: illustration with imipenem muscle distribution.

Authors:  Claire Dahyot; Sandrine Marchand; Mikael Bodin; Bertrand Debeane; Olivier Mimoz; William Couet
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Penetration of antibacterials into bone: what do we really need to know for optimal prophylaxis and treatment of bone and joint infections?

Authors:  Federico Pea
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Tissue pharmacokinetics of levofloxacin in human soft tissue infections.

Authors:  Romuald Bellmann; Gerald Kuchling; Pejman Dehghanyar; Markus Zeitlinger; Erich Minar; Bernhard X Mayer; Markus Müller; Christian Joukhadar
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

10.  Similar maximum systemic but not local cyclooxygenase-2 inhibition by 50 mg lumiracoxib and 90 mg etoricoxib: a randomized controlled trial in healthy subjects.

Authors:  Lisa Felden; Carmen Walter; Carlo Angioni; Yannick Schreiber; Nils von Hentig; Nerea Ferreiros; Gerd Geisslinger; Jörn Lötsch
Journal:  Pharm Res       Date:  2014-01-28       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.